Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

26.10USD
28 Mar 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$26.10
Open
--
Day's High
--
Day's Low
--
Volume
45
Avg. Vol
774,903
52-wk High
$33.00
52-wk Low
$16.40

Latest Key Developments (Source: Significant Developments)

Acorda Therapeutics Inc gives FY 2016 AMPYRA net sales guidance
Monday, 11 Jan 2016 07:30am EST 

Acorda Therapeutics Inc:Expects AMPYRA FY 2016 net sales guidance of $475 mln - $485 mln.  Full Article

Acorda Therapeutics Inc raises FY 2015 AMPYRA net revenue guidance
Thursday, 22 Oct 2015 06:00am EDT 

Acorda Therapeutics Inc:Raised FY 2015 guidance for AMPYRA net revenue from $410-$420 million to $420-$430 million.  Full Article

Acorda Therapeutics Inc raises low end of prior FY 2015 AMPYRA net sales guidance
Thursday, 30 Jul 2015 06:00am EDT 

Acorda Therapeutics Inc:Expects FY 2015 AMPYRA net sales guidance in the range of $410-$420 million.  Full Article

Acorda Therapeutics presents data on inhaled levodopa therapy CVT-301
Tuesday, 16 Jun 2015 07:00am EDT 

Acorda Therapeutics:Presents data on inhaled levodopa therapy cvt-301 at international congress of parkinson's disease and movement disorders.Trial showed that patients treated with cvt-301, showed significantly greater improvements in motor function versus placebo.Participants receiving cvt-301 showed statistically significant,clinically important reduction in average updrs III motor score.Says there were no serious adverse events reported in the drug group.Says the incidence of drug-related adverse events was similar between treatment groups.Says pd patients were able to self-administer treatment while in an off state.  Full Article

Acorda Therapeutics Inc reaffirms FY 2015 Ampyra revenue guidance - Conference Call
Tuesday, 2 Jun 2015 07:30pm EDT 

Acorda Therapeutics Inc:Projects FY 2015 net sales of $405 million to $420 million for Ampyra in MS.  Full Article

More From Around the Web